250 related articles for article (PubMed ID: 17212810)
41. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
42. Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3.
de Rozières S; Swan CH; Sheeter DA; Clingerman KJ; Lin YC; Huitron-Resendiz S; Henriksen S; Torbett BE; Elder JH
Retrovirology; 2004 Nov; 1():38. PubMed ID: 15555065
[TBL] [Abstract][Full Text] [Related]
43. Three-dimensional structures of HIV-1 and SIV protease product complexes.
Rose RB; Craik CS; Douglas NL; Stroud RM
Biochemistry; 1996 Oct; 35(39):12933-44. PubMed ID: 8841139
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
Kovalevsky AY; Tie Y; Liu F; Boross PI; Wang YF; Leshchenko S; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2006 Feb; 49(4):1379-87. PubMed ID: 16480273
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
Liu F; Kovalevsky AY; Louis JM; Boross PI; Wang YF; Harrison RW; Weber IT
J Mol Biol; 2006 May; 358(5):1191-9. PubMed ID: 16569415
[TBL] [Abstract][Full Text] [Related]
47. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.
Menéndez-Arias L; Weber IT; Soss J; Harrison RW; Gotte D; Oroszlan S
J Biol Chem; 1994 Jun; 269(24):16795-801. PubMed ID: 8207003
[TBL] [Abstract][Full Text] [Related]
48. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
49. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.
Kovalevsky AY; Liu F; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2006 Oct; 363(1):161-73. PubMed ID: 16962136
[TBL] [Abstract][Full Text] [Related]
50. Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease.
Sperka T; Boross P; Eizert H; Tözsér J; Bagossi P
Protein Eng Des Sel; 2006 Aug; 19(8):369-75. PubMed ID: 16799151
[TBL] [Abstract][Full Text] [Related]
51. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
[TBL] [Abstract][Full Text] [Related]
52. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.
Strisovsky K; Tessmer U; Langner J; Konvalinka J; Kräusslich HG
Protein Sci; 2000 Sep; 9(9):1631-41. PubMed ID: 11045610
[TBL] [Abstract][Full Text] [Related]
53. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Auwerx J; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
[TBL] [Abstract][Full Text] [Related]
54. Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors.
Petroková H; Dusková J; Dohnálek J; Skálová T; Vondrácková-Buchtelová E; Soucek M; Konvalinka J; Brynda J; Fábry M; Sedlácek J; Hasek J
Eur J Biochem; 2004 Nov; 271(22):4451-61. PubMed ID: 15560786
[TBL] [Abstract][Full Text] [Related]
55. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases.
Hong L; Treharne A; Hartsuck JA; Foundling S; Tang J
Biochemistry; 1996 Aug; 35(33):10627-33. PubMed ID: 8718851
[TBL] [Abstract][Full Text] [Related]
56. Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap.
Gustchina A; Weber IT
FEBS Lett; 1990 Aug; 269(1):269-72. PubMed ID: 2201571
[TBL] [Abstract][Full Text] [Related]
57. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
Mahalingam B; Louis JM; Reed CC; Adomat JM; Krouse J; Wang YF; Harrison RW; Weber IT
Eur J Biochem; 1999 Jul; 263(1):238-45. PubMed ID: 10429209
[TBL] [Abstract][Full Text] [Related]
58. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
59. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.
Sayer JM; Liu F; Ishima R; Weber IT; Louis JM
J Biol Chem; 2008 May; 283(19):13459-70. PubMed ID: 18281688
[TBL] [Abstract][Full Text] [Related]
60. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
